Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts

被引:30
|
作者
Jacobi, Angela [1 ]
Thieme, Sebastian [1 ,2 ]
Lehmann, Romy [1 ]
Ugarte, Fernando [1 ]
Malech, Harry L. [3 ]
Koch, Sina [4 ]
Thiede, Christian [2 ,4 ]
Mueller, Katrin [4 ]
Bornhaeuser, Martin [2 ,4 ]
Ryser, Martin [1 ]
Brenner, Sebastian [1 ,2 ]
机构
[1] Univ Clin Carl Gustav Carus Dresden, Dept Pediat, D-01307 Dresden, Germany
[2] Tech Univ Dresden, DFG Res Ctr & Cluster Excellence Regenerat Therap, Dresden, Germany
[3] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
[4] Univ Clin Carl Gustav Carus Dresden, Med Clin 1, D-01307 Dresden, Germany
关键词
ACUTE MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD; FLT3; MUTATIONS; FLT3-ACTIVATING MUTATIONS; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; STEM-CELLS; SURVIVAL; ENGRAFTMENT; CHEMOTAXIS;
D O I
10.1016/j.exphem.2009.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AMI, blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition. Materials and Methods. We use primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, human CD34(+) hematopoietic progenitor cells were transduced to >70% with retroviral vectors containing human FLT3-ITD. Results. We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor-1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficient mice. Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells oil bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD. Conclusion. CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden play provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML. (C) 2010 ISEH - Society for Hematology and Stern Cells. Published by Elsevier Inc.
引用
收藏
页码:180 / 190
页数:11
相关论文
共 50 条
  • [31] CCL5 mediates Target-Kinase independent resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD-positive AML
    Waldeck, S.
    Rassner, M.
    Philipp, U.
    Andrieux, G.
    Keye, P.
    Waterhouse, M.
    Duyster, J.
    von Bubnoff, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 143 - 143
  • [32] CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
    Kim, Bo-Reum
    Jung, Seung-Hyun
    Han, A-Reum
    Park, Gyeongsin
    Kim, Hee-Je
    Yuan, Bin
    Battula, Venkata Lokesh
    Andreeff, Michael
    Konopleva, Marina
    Chung, Yeun-Jun
    Cho, Byung-Sik
    CANCERS, 2020, 12 (07) : 1 - 16
  • [33] LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML
    Beeharry, Neil
    Landrette, Sean
    Gayle, Sophia
    Hernandez, Marylens
    Grotzke, Jeff E.
    Young, Peter R.
    Beckett, Paul
    Zhang, Xuan
    Carter, Bing Z.
    Andreeff, Michael
    Halene, Stephanie
    Xu, Tian
    Rothberg, Jonathan
    Lichenstein, Henri
    BLOOD ADVANCES, 2019, 3 (22) : 3661 - 3673
  • [34] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
    Jeon, Jae Yoon
    Zhao, Qiuhong
    Buelow, Daelynn R.
    Phelps, Mitch
    Walker, Alison R.
    Mims, Alice S.
    Vasu, Sumithira
    Behbehani, Gregory
    Blachly, James
    Blum, William
    Klisovic, Rebecca B.
    Byrd, John C.
    Garzon, Ramiro
    Baker, Sharyn D.
    Bhatnagar, Bhavana
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 340 - 349
  • [35] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
    Jae Yoon Jeon
    Qiuhong Zhao
    Daelynn R. Buelow
    Mitch Phelps
    Alison R. Walker
    Alice S. Mims
    Sumithira Vasu
    Gregory Behbehani
    James Blachly
    William Blum
    Rebecca B. Klisovic
    John C. Byrd
    Ramiro Garzon
    Sharyn D. Baker
    Bhavana Bhatnagar
    Investigational New Drugs, 2020, 38 : 340 - 349
  • [36] Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
    Kannan, Sankaranarayan
    Irwin, Mary E.
    Herbrich, Shelley M.
    Cheng, Tiewei
    Patterson, LaNisha L.
    Aitken, Marisa J. L.
    Bhalla, Kapil
    You, M. James
    Konopleva, Marina
    Zweidler-McKay, Patrick A.
    Chandra, Joya
    ANTIOXIDANTS, 2022, 11 (04)
  • [37] Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML
    Wang, Aoli
    Wu, Hong
    Chen, Cheng
    Hu, Chen
    Qi, Ziping
    Wang, Wenchao
    Yu, Kailin
    Liu, Xiaochuan
    Zou, Fengming
    Zhao, Zheng
    Wu, Jiaxin
    Liu, Juan
    Liu, Feiyang
    Wang, Li
    Stone, Richard M.
    Galinksy, Ilene A.
    Griffin, James D.
    Zhang, Shanchun
    Weisberg, Ellen L.
    Liu, Jing
    Liu, Qingsong
    ONCOTARGET, 2016, 7 (20) : 29131 - 29142
  • [38] INTERNAL TANDEM DUPLICATION (ITD) MUTATIONS OF THE FLT3 RECEPTOR AND CXCR4 EXPRESSION IN DE NOVO ADULT ACUTE MYELOID LEUKEMIAS (AML)
    Improta, S.
    Gagliardi, A.
    Quirino, A.
    Tommasino, C.
    Mastrullo, L.
    HAEMATOLOGICA, 2012, 97 : 506 - 506
  • [39] INTERNAL TANDEM DUPLICATION (ITD) MUTATIONS OF THE FLT3 RECEPTOR AND CXCR4 EXPRESSION IN DE NOVO ADULT ACUTE MYELOID LEUKEMIAS (AML)
    Villa, M. R.
    Della Cioppa, P.
    Cuccurullo, R.
    Esposito, M.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 569 - 569
  • [40] TARGETING THE DBC1-SIRT1-P53 AXIS IS A PROMISING THERAPEUTIC STRATEGY IN FLT3-ITD-POSITIVE AML
    Sasca, D.
    Haehnel, P.
    Al-Khawaja, K.
    Bullinger, L.
    Theobald, M.
    Kindler, T.
    HAEMATOLOGICA, 2013, 98 : 401 - 401